The global burden of viral hepatitis
By Dr Graham Cooke, Clinical Senior Lecturer in Infectious Diseases, Imperial College London
A couple of weeks ago we published our paper on the burden of viral hepatitis. We’d hoped that the Lancet would publish it in time for World Health Assembly in May and it might get a bit of attention. That couldn’t be done, so it came out on the 6th July. The same day as Chilcot. Not a brilliant piece of planning, it has to be said, and a reminder of how much I have to learn about PR.
With colleagues at Imperial, we have been studying and writing about hepatitis for some years. But there’s always been a feeling that hepatitis has been relatively low profile in the global health community, and not just because of major enquiries into wars. So how did we end up writing a paper on the burden of hepatitis?
Most of the health impact of viral hepatitis is from two viruses, hepatitis B (HBV) and hepatitis C (HCV) – both cause liver scarring (cirrhosis) and liver cancer (hepatocellular carcinoma). The world has had a good HBV vaccine for a long time, and in the last few years we have seen great progress in new treatments for both viruses. Hepatitis B can be controlled, like HIV, with daily medication. But a revolution in treatment really kicked off in late 2011 when data was presented on the first a new class of curative treatments for hepatitis C, sofosbuvir (then known catchily as PSI-7977). As soon as we saw that data it was clear that the step forward in treatment could transform treatment, not just in developed health systems, but potentially in all health systems. (more…)